• Estimated cost reduction of $5M from FY2027
• Transition to outsourced product development
• Broadened product offering to address more customer needs

Genetic Signatures Ltd [ASX: GSS] has announced a significant organisational restructure designed to reduce operating costs, improve efficiency, and sharpen the company's focus on sales growth, customer support and the broadening of its diagnostic product offering. The proposed changes follow a thorough review of the company's operating structure, aimed at aligning resources with strategic priorities. The restructuring is expected to result in up to 30 redundancies and estimated cost savings of $5 million from FY2027, with one-off redundancy costs of approximately $800K. The company will transition elements of product development to specialist contract research organisations, while maintaining core intellectual property and technical capabilities in-house. This model is intended to provide the company with access to flexible, best-in-class product development whilst reducing fixed costs and improving speed to market. The company also intends to increase its focus on expanding its product portfolio, including advancing new product initiatives and compiling and publishing clinical data for the existing product portfolio, with the goal of addressing a broader range of customer needs, clinical applications and targeting new markets.

The proposed restructuring is expected to result in estimated cost savings of $5 million from FY2027.

The company believes that a stronger commercial and customer-facing organisation is essential to driving product adoption in priority geographies and market segments. The restructure marks an important step in positioning the company for sustainable growth.